MedPlus Health Services Limited has announced that its promoters have executed a debenture trust deed as part of a debt refinancing initiative. The company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, highlighting significant financial arrangements by its promoter entities.

Debenture Trust Deed Details

The promoters of MedPlus Health Services Limited executed the debenture trust deed with Catalyst Trusteeship Limited. The key parties involved in this agreement include:

Financial Terms and Structure

The debenture arrangement encompasses significant financial commitments designed to facilitate debt refinancing operations. The structure includes specific interest rates and principal amounts that will impact the company's financial positioning.

Share Pledge Implications

The refinancing transaction involves temporary changes to the promoter group's share pledge arrangements. The incremental pledge is proposed in connection with refinancing Agilemed Investments Private Limited's existing debt through NCD issuance.

During the refinancing transaction and interim period, the pledge dynamics will evolve as follows:

• Current pledge level: 23.91% of shares already pledged
• Temporary increase: Pledge will rise to 27.96% during refinancing
• Expected final level: 24.48% upon successful debt refinancing completion

The aggregate promoter group share pledge is expected to reduce to 24.48% upon successful completion of debt refinancing and consequent release of existing pledged shares by the current lender, following receipt of payment according to agreed terms.

Regulatory Compliance

The company has fulfilled its disclosure obligations under SEBI regulations, providing comprehensive details about the agreement and its implications. The disclosure covers all aspects required under Regulation 30 and 30A read with clause 5A of Para A Part A of Schedule III of SEBI LODR and the SEBI Master circular.

The information will be made available on the company's website at www.medplusindia.com and on the websites of BSE Limited and National Stock Exchange of India Limited for stakeholder access and transparency.

Medplus Health Services Limited has informed stock exchanges about regulatory action taken against its subsidiary, involving the suspension of drug licenses for multiple store locations in Maharashtra.

Subsidiary Faces License Suspension Orders

Optival Health Solutions Private Limited, a subsidiary of Medplus Health Services, has received three suspension orders for drug licenses affecting stores in Maharashtra. The orders were received on December 13, 2025, from the Assistant Commissioner Licensing Authority, Food Drug Administration, Maharashtra.

The suspensions target stores located in Amravati and Nagpur districts, with each suspension lasting five days. The regulatory action has been taken under Rule 65 of the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945.

Financial Impact Assessment

The company has quantified the potential revenue impact from these license suspensions across the affected locations:

The total potential revenue loss across the affected locations is estimated at ₹10.17 lakhs.

Regulatory Compliance and Disclosure

The disclosure has been made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, read with SEBI Circular SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024. These regulations require listed entities to disclose material events affecting their operations or subsidiaries.

The company has stated that detailed information regarding this matter will be available on its official website at www.medplusindia.com , as well as on the websites of BSE Limited and National Stock Exchange of India Limited. This ensures transparency and accessibility of information for all stakeholders and regulatory compliance requirements.